Booth: 909
DCISionRT by PreludeDx is the only DCIS test that predicts radiation therapy benefit. The test provides a Decision Score along a continuum from 0 to 10, that stratifies a woman’s risk of 10-yr local recurrence as low, elevated or residual risk. Unlike other risk assessment tools, the DCISionRT test combines protein expression from seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions between biologic factors to provide a better assessment of the patient’s individual tumor biology. DCISionRT’s intelligent reporting provides a woman’s risk of recurrence after breast conserving surgery (BCS) alone, and with the addition of radiation therapy (RT). The personalized results of this new biologic information helps patients and physicians to make more informed treatment decisions and facilitate the shared decision-making process.
